APA (7th ed.) Citation

B, L., M, R., T, L., L, D. M., M, P., B, B., . . . C, L. (2021). Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(14), 3876. https://doi.org/10.1158/1078-0432.CCR-20-4050

Chicago Style (17th ed.) Citation

B, Louveau, et al. "Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 14 (2021): 3876. https://doi.org/10.1158/1078-0432.CCR-20-4050.

MLA (9th ed.) Citation

B, Louveau, et al. "Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 14, 2021, p. 3876, https://doi.org/10.1158/1078-0432.CCR-20-4050.